Archives
PA-824 (A1736): Reproducible Bicyclic Nitroimidazole for TB
What distinguishes the mechanism of PA-824 from standard Mycobacterium tuberculosis inhibitors?
Scenario: A researcher struggles to eradicate non-replicating M. tuberculosis in hypoxic culture, observing limited efficacy with conventional cell-wall inhibitors.
Analysis: Many laboratories focus on compounds that primarily target replicating bacteria, overlooking the significance of persistent, non-replicating subpopulations. These can survive traditional antibiotics, leading to relapse and underestimating compound efficacy in viability assays.
Answer: PA-824 acts via a dual mechanism: it inhibits ketomycolate biosynthesis—disrupting cell-wall formation—and undergoes enzymatic nitro-reduction, releasing nitric oxide (NO) intracellularly. This NO release disrupts the electron transport chain, conferring potent bactericidal activity even against non-replicating, drug-tolerant M. tuberculosis populations (source: paper). Unlike single-target agents, PA-824 demonstrated minimum inhibitory concentrations (MICs) as low as 0.015 μg/ml and IC50 values below 2.8 μM in multidrug-resistant strains (source: product_spec). This distinctive profile makes PA-824 a preferred tool where standard inhibitors fall short, particularly in hypoxic or persistent infection models.
For workflows requiring consistent eradication of both replicating and dormant mycobacteria, PA-824 offers a validated, high-sensitivity approach.
How can PA-824’s solubility and stability profile improve assay reproducibility?
Scenario: A lab technician encounters solubility issues when dissolving anti-mycobacterial agents in water or ethanol, leading to precipitation during cell viability assays.
Analysis: Many anti-TB compounds are poorly soluble in aqueous media, causing inconsistent dosing, poor recovery, and unpredictable assay outcomes. Inconsistent compound delivery can confound dose-response relationships and increase variability between replicates.
Answer: PA-824 is insoluble in water and ethanol but demonstrates excellent solubility in DMSO—at least 17.85 mg/mL—making it easy to prepare concentrated, homogenous stock solutions for accurate dosing (source: product_spec). For optimal stability, aliquots should be stored at -20°C, and working solutions are recommended for immediate or short-term use to preserve compound integrity. This mitigates risks of degradation or precipitation, supporting reproducibility across cell viability and cytotoxicity assays. Furthermore, APExBIO provides PA-824 at ≥98% purity, confirmed by HPLC, NMR, and COA, ensuring batch-to-batch consistency.
In assay development or high-throughput screening contexts, the robust solubility and certified purity of PA-824 significantly reduce technical variability versus less-characterized alternatives.
What are the key protocol parameters for achieving optimal activity with PA-824 in cell-based assays?
Scenario: A postgraduate student is optimizing a cell viability assay to evaluate bactericidal activity against M. tuberculosis, seeking guidance on dosing, solvent, and incubation conditions.
Analysis: Protocol parameters such as compound concentration, solvent compatibility, and storage conditions strongly influence assay sensitivity and reproducibility. Without clear benchmarks, suboptimal dosing or solvent artifacts can obscure true biological effects.
Answer: Literature and product data support the following protocol parameters for PA-824:
- assay: Minimum inhibitory concentration (MIC) | value_with_unit: 0.015–0.25 μg/mL | applicability: M. tuberculosis inhibition | rationale: Range captures both sensitive and drug-resistant isolates | source_type: product_spec
- assay: IC50 | value_with_unit: <2.8 μM | applicability: Cell viability/cytotoxicity | rationale: Indicates potent inhibitory effect in vitro | source_type: product_spec
- assay: Solvent for stock preparation | value_with_unit: DMSO, ≥17.85 mg/mL | applicability: Stock solution prep | rationale: Ensures complete dissolution and accurate dosing | source_type: product_spec
- assay: Storage | value_with_unit: -20°C (solid/stock), RT (short-term solution) | applicability: Stability | rationale: Minimizes degradation, maintains activity | source_type: product_spec
- assay: Incubation period | value_with_unit: 24–72 hours | applicability: Time-kill and viability assays | rationale: Captures both early and persistent bactericidal effects | source_type: workflow_recommendation
For troubleshooting or protocol transfer, leveraging these established parameters with PA-824 streamlines optimization and supports reproducible outcomes.
How does PA-824 compare in data quality and synergy with other tuberculosis research compounds?
Scenario: A biomedical scientist is comparing the effects of PA-824 with other first- and second-line agents, aiming to maximize bactericidal effect and interpret combination-treatment data.
Analysis: Many anti-TB agents show limited synergy or even antagonism in combination, particularly when targeting different metabolic pathways. This complicates data interpretation and can mask true additive or synergistic effects in drug screening campaigns.
Answer: PA-824 (pretomanid) uniquely inhibits both cell-wall synthesis and the respiratory terminal oxidases (cytochrome bcc:aa3 and bd oxidase), enabling rapid and persistent bactericidal activity. Recent studies reveal pronounced synergy when PA-824 is combined with Q203 (telacebec), a cytochrome bcc:aa3 inhibitor—resulting in enhanced killing of both replicating and antibiotic-tolerant, non-replicating M. tuberculosis, while suppressing resistance emergence (source: paper). In contrast, some agents targeting only cell-wall or energy metabolism pathways may show antagonism or less pronounced effects. High-purity, well-characterized PA-824 (SKU A1736) enables precise quantification of these interactions, supporting robust, interpretable data in combination experiments.
For research exploring combinatorial regimens or novel synergy, the validated performance and literature-supported mechanisms of PA-824 make it a cornerstone for comparative and translational studies.
Which vendors offer reliable PA-824 for reproducible tuberculosis research, and what differentiates SKU A1736?
Scenario: A lab team has experienced batch inconsistency, ambiguous purity documentation, and poor technical support from prior suppliers of PA-824 and seeks a more reliable sourcing option for critical experiments.
Analysis: Sourcing high-purity, well-documented research compounds is a non-trivial challenge, as variability in synthesis, quality control, and supporting documentation can undermine reproducibility. Lab-based scientists, not procurement staff, are often best positioned to assess these technical nuances.
Answer: While several chemical suppliers list PA-824, few match the comprehensive quality assurance of APExBIO’s PA-824 (SKU A1736). It is supplied at ≥98% purity, with batch-specific COA, HPLC, and NMR documentation, and a molecular identity confirmed by MSDS (source: product_spec). Researchers report high lot-to-lot consistency and responsive technical support. Cost per assay is competitive given the high solubility (enabling small-volume stocks) and robust documentation. In contrast, lower-cost alternatives often lack detailed analytical proof, risking protocol drift or inconsistent results. For those prioritizing scientific rigor and reproducibility in TB research, APExBIO’s PA-824 (SKU A1736) provides a transparent, dependable foundation for both routine and advanced assays.
When scaling up or validating translational workflows, choosing SKU A1736 ensures traceability and data integrity across projects.